A Strong Humoral Immune Response Induced by a Vaccine Formulation Containing rSm29 Adsorbed to Alum Is Associated With Protection Against Schistosoma mansoni Reinfection in Mice

Alves, Clarice Carvalho; Araújo, Neusa; Bernardes, Wilma Patrícia de Oliveira Santos; Mendes, Mariana Moreira; Oliveira, Sérgio C.; Fonseca, Cristina Toscano

doi:10.3389/fimmu.2018.02488

Cited by 8 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of digestive symptoms such as diarrhea, are known to be associated with a dysbiosis of the gut microbiome [ 233 ]. Furthermore, the role of the gut microbiome in the predisposition to and severity of viral infection is already recognized [ 234 , 235 ]. This role is mostly due to the impact of the gut microbiome on the systemic immune system.…”

Section: Covid 19: Relevance Of Host Genetic Factorsmentioning

confidence: 99%

Host factors facilitating SARS‐CoV‐2 virus infection and replication in the lungs

Boutin

Hildebrand

Boulant

et al. 2021

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

SARS-CoV-2 is the virus causing the major pandemic facing the world today. Although, SARS-CoV-2 primarily causes lung infection, a variety of symptoms have proven a systemic impact on the body. SARS-CoV-2 has spread in the community quickly infecting humans from all age, ethnicities and gender. However, fatal outcomes have been linked to specific host factors and co-morbidities such as age, hypertension, immuno-deficiencies, chronic lung diseases or metabolic disorders. A major shift in the microbiome of patients suffering of the coronavirus disease 2019 (COVID-19) have also been observed and is linked to a worst outcome of the disease. As many co-morbidities are already known to be associated with a dysbiosis of the microbiome such as hypertension, diabetes and metabolic disorders. Host factors and microbiome changes are believed to be involved as a network in the acquisition of the infection and the development of the diseases. We will review in detail in this manuscript, the immune response toward SARS-CoV-2 infection as well as the host factors involved in the facilitation and worsening of the infection. We will also address the impact of COVID-19 on the host’s microbiome and secondary infection which also worsen the disease.

show abstract

Section: Covid 19: Relevance Of Host Genetic Factorsmentioning

confidence: 99%

Host factors facilitating SARS‐CoV‐2 virus infection and replication in the lungs

Boutin

Hildebrand

Boulant

et al. 2021

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

show abstract

“…In particular, mice immunized with Sm29Alum formulation showed higher production of IgG, IgG1, and IgE after all immunization doses. Having concluded that, Sm29Alum can effectively protect against S. mansoni reinfection in mice ( Alves et al, 2018 ).…”

Section: Current Status Of Protein Vaccine Candidates Against mentioning

confidence: 99%

Current status and future prospects of protein vaccine candidates against Schistosoma mansoni infection

Eyayu

Zeleke

Worku

2020

Parasite Epidemiology and Control

View full text Add to dashboard Cite

Schistosomiasis is an acute and chronic tropical parasitic disease caused by blood dwelling worm of the genus Schistosoma. It is the most destructive disease globally and is a major cause of morbidity and mortality for developing countries. Three main species of schistosomes infect human beings from which S. mansoni is the most common and widespread. Over the last several decades, chemotherapy using praziquantel has been a commonly used strategy for the treatment and control of schistosomiasis. However, control programs focused exclusively on chemotherapy have been challenging because of the frequency and rapidity of reinfection and these programs were expensive. Thus, new schistosomiasis control strategies will be needed. Vaccination strategy would be an ideal tool for a significant and sustainable reduction in the transmission and disease burden of schistosomiasis. An effective anti schistosome vaccine would greatly contribute to decreasing schistosomiasis-associated morbidity via protective immune responses leading to reduced worm burdens and decreased egg production. Vaccine development is a long process that can take decades. There have been three candidate vaccines that have been produced by Good Manufacturing Procedure and entered human clinical trials for S. mansoni are Sm14, SmTSP-2, and Sm-p80. Other candidates that are in pre-clinical trials at various stages include paramyosin, Sm29, SmKI-1, and Sm23. Since the growth of several new technologies, including genomics, transcriptomics, microarrays, immunomic profiling, and proteomics, have helped in the identification of promising new target schistosome antigens. Therefore, this review considers the present status of protein vaccine candidates against Schistosoma mansoni and provides some insight on prospects vaccine design and discovery.

show abstract

“…The combination of Sm29 and Sm14 induces significant protective immunity in mice infected with S. mansoni [34]. A vigorous humoral immune response can be induced by a vaccine formulation containing rSm29 adsorbed to alum, which successfully protects against S. mansoni reinfection in mice, indicating a potentially effective vaccine formulation that could be used in humans [35]. Sj29 is homologous to Sm29 of S. mansoni , which was characterized by our group as a membrane-bound antigen in S. japonicum [20].…”

Section: Discussionmentioning

confidence: 99%

An Efficient Schistosoma japonicum Bivalent Membrane Protein Antigen DNA Vaccine Against Schistosomiasis in Mice

et al. 2019

View full text Add to dashboard Cite

BackgroundSchistosomiasis is one of the most important infectious parasitic diseases in the world. The most important was to control schistosomiasis is through a combination of medical therapy and immunization. The membrane antigens Tsp2 and 29 from Schistosoma are promising anti-schistosomiasis vaccine candidates.Material/MethodsIn this study, the pcDNA3.1(+)-SjTsp2, pcDNA3.1(+)-Sj29, and pcDNA3.1 (+)-SjTsp2-29 eukaryotic expression vectors were successfully constructed as DNA vaccines, and the protective abilities of these vaccines were evaluated in mice.ResultsThe results showed that vaccination with SjTsp2, Sj29, and SjTsp2-29 reduced parasite burden and hepatic pathology compared to the control group, and the protective effect of the bivalent SjTsp2-29 DNA vaccine was better than that of the univalent SjTsp2 or Sj29 DNA vaccines. We also found high levels of IgG, IgG1, and IgG2a against SjTsp2, Sj29, and SjTsp2-29 DNA vaccines, with high expression of IFN-γ and no IL-4 in the mice.ConclusionsThe double-membrane antigen DNA vaccine SjTsp2-29 elicited protection against Schistosoma infection and might serve as a vaccine candidate.

show abstract

A Strong Humoral Immune Response Induced by a Vaccine Formulation Containing rSm29 Adsorbed to Alum Is Associated With Protection Against Schistosoma mansoni Reinfection in Mice

Cited by 8 publications

References 35 publications

Host factors facilitating SARS‐CoV‐2 virus infection and replication in the lungs

Host factors facilitating SARS‐CoV‐2 virus infection and replication in the lungs

Current status and future prospects of protein vaccine candidates against Schistosoma mansoni infection

An Efficient Schistosoma japonicum Bivalent Membrane Protein Antigen DNA Vaccine Against Schistosomiasis in Mice

Contact Info

Product

Resources

About